Re: Association between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Urology

• Publication date

  2017-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.juro.2017.09.065PMID 29144945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy.

  2016cited by this paper
• Pricing in the Market for Anticancer Drugs.

  2015cited by this paper
• Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.

  2015cited by this paper
• A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer.

  2015cited by this paper
• Prostate cancer: Improving early detection—can PCA3 do more?

  2015cited by this paper
• Radical prostatectomy or watchful waiting in early prostate cancer.

  2014cited by this paper
• Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

  2014cited by this paper
• Can urinary PCA3 supplement PSA in the early detection of prostate cancer?

  2014cited by this paper
• Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy.

  2014cited by this paper
• The cost implications of prostate cancer screening in the Medicare population

  2014cited by this paper
• PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

  2013cited by this paper
• Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer

  2013cited by this paper
• Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.

  2013cited by this paper
• Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

  2013cited by this paper
• Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.

  2012cited by this paper
• The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

  2012cited by this paper
• Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden.

  2012cited by this paper
• Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

  2012cited by this paper
• The relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance

  2012cited by this paper
• Radical prostatectomy versus observation for localized prostate cancer.

  2012cited by this paper
• Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging.

  2011cited by this paper
• Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions.

  2011cited by this paper
• A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.

  2011cited by this paper
• Lifetime economic burden of prostate cancer

  2011cited by this paper
• Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

  2011cited by this paper
• Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

  2010cited by this paper
• Mortality results from a randomized prostate-cancer screening trial.

  2009cited by this paper
• Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Fusion in the ETS gene family and prostate cancer

  2008cited by this paper
• PCA3: a molecular urine assay for predicting prostate biopsy outcome.

  2008cited by this paper
• Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design

  2008cited by this paper
• Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer

  2007cited by this paper
• PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy.

  2007cited by this paper
• Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

  2006cited by this paper
• 20-year outcomes following conservative management of clinically localized prostate cancer.

  2005cited by this paper
• Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer

  2005cited by this paper
• 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

  2004cited by this paper
• DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

  2003cited by this paper
• DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.

  1999cited by this paper
• Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

  1997cited by this paper

• Review on Recent Advances in Urinary Biomarkers Based Electrochemical Sensors for Prostate Cancer Detection

  2021cites this paper
• Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study

  2021cites this paper
• Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review

  2021cites this paper
• Beyond PSA: The Role of Prostate Health Index (phi)

  2020cites this paper
• Targetable gene fusions and aberrations in genitourinary oncology

  2020cites this paper
• Challenges and Opportunities of Genomic Approaches in Therapeutics Development.

  2020cites this paper
• Non-coding RNAs: the new central dogma of cancer biology

  2020cites this paper
• Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups.

  2020cites this paper
• Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies

  2020cites this paper
• Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes

  2020cites this paper
• Cancer Progress and Priorities: Prostate Cancer

  2020cites this paper
• Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice.

  2020cites this paper
• Evaluating liquid biopsies for methylomic profiling of prostate cancer

  2020cites this paper
• Impact of the MyProstateScore (MPS) test on the clinical decision to undergo prostate biopsy: results from a contemporary academic practice

  2020cites this paper
• Identification of transcription factor co-regulators that drive prostate cancer progression

  2020cites this paper
• Urinary glycoproteins associated with aggressive prostate cancer

  2020cites this paper
• The genetic landscapes of urological cancers and their clinical implications in the era of high‐throughput genome analysis

  2020cites this paper
• How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?

  2020cites this paper
• Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review

  2020cites this paper
• A New Era of Prostate Cancer Precision Medicine

  2019cites this paper
• Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.

  2019cites this paper
• Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer

  2019cites this paper
• Long non-coding RNAs in prostate cancer: Biological and clinical implications.

  2019cites this paper
• APPROACHES TO URINARY DETECTION OF PROSTATE CANCER

  2019cites this paper
• Recent advances in extracellular vesicle research for urological cancers: From technology to application.

  2019cites this paper
• A novel approach for assessment of prostate cancer aggressiveness using survivin-driven tumour-activatable minicircles

  2019cites this paper
• Active Surveillance und die moderne Diagnostik des Prostatatkarzinoms

  2019cites this paper
• Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management

  2019cites this paper
• Cancer overdiagnosis: a biological challenge and clinical dilemma

  2019cites this paper
• Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery

  2019cites this paper
• Unifying Next-Generation Biomarkers and Nanodiagnostic Platforms for Precision Prostate Cancer Management

  2019cites this paper
• Prostate cancer and the role of biomarkers

  2019cites this paper
• The long non-coding RNA PCA3: an update of its functions and clinical applications as a biomarker in prostate cancer

  2019cites this paper
• The Tumor Microenvironments of Lethal Prostate Cancer.

  2019cites this paper
• Urinary extracellular vesicle biomarkers in urological cancers: From discovery towards clinical implementation.

  2018cites this paper
• Genomic Markers in Prostate Cancer Decision Making.

  2018cites this paper
• Urinmarker – alter Wein in neuen Schläuchen?

  2018cites this paper
• Study Design Considerations for Cancer Biomarker Discoveries.

  2018cites this paper
• Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)

  2018cites this paper
• Early Detection Research Network: Accomplishments and Outlook.

  2018cites this paper
• Novel Biomarkers for Prostate Cancer Detection and Prognosis.

  2018cites this paper
• The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression

  2018cites this paper
• The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection

  2018cites this paper
• Liquid biopsy approach in the management of prostate cancer.

  2018cites this paper
• Targetable long non-coding RNAs in cancer treatments.

  2018cites this paper
• Molecular Biomarkers in the Clinical Management of Prostate Cancer.

  2018cites this paper
• Clinical utility of circulating non-coding RNAs — an update

  2018cites this paper
• Clinical and Novel Biomarkers in the Management of Prostate Cancer

  2018cites this paper
• Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.

  2018cites this paper
• The miR-96/RARγ signaling axis governs androgen signaling and prostate cancer progression

  2017cites this paper